Related Experiment Video
Updated: Mar 2, 2026
Expression, Isolation, and Purification of Soluble and Insoluble Biotinylated Proteins for Nerve Tissue Regeneration
Published on: January 22, 2014
The Challenges of Recombinant Endostatin in Clinical Application: Focus on the Different Expression Systems and
Abbas Mohajeri1,2, Sarvin Sanaei2, Farhad Kiafar1
1Department of Biotechnology, Zahravi Pharmaceutical Company, Tabriz, Iran.
Abstract:
Angiogenesis plays an essential role in rapid growing and metastasis of the tumors. Inhibition of angiogenesis is a putative strategy for cancer therapy. Endostatin (Es) is an attractive anti-angiogenesis protein with some clinical application challenges including; short half-life, instability in serum and requirement to high dosage. Therefore, production of recombinant endostatin (rEs) is necessary in large scale. The production of rEs is difficult because of its structural properties and is high-cost. Therefore, this review focused on the different expression systems that involved in rEs production including; mammalian, baculovirus, yeast, and Escherichia coli (E. coli) expression systems. The evaluating of the results of different expression systems declared that none of the mentioned systems can be considered to be generally superior to the other. Meanwhile with considering the advantages and disadvantage of E. coli expression system compared with other systems beside the molecular properties of Es, E. coli expression system can be a preferred expression system for expressing of the Es in large scale. Also, the molecular bioengineering and sustained release formulations that lead to improving of its stability and bioactivity will be discussed. Point mutation (P125A) of Es, addition of RGD moiety or an additional zinc biding site to N-terminal of Es , fusing of Es to anti-HER2 IgG or heavy-chain of IgG, and finally loading of the endostar by PLGA and PEG- PLGA nanoparticles and gold nano-shell particles are the effective bioengineering methods to overcome to clinical changes of endostatin.
Insights
Recombinant endostatin (rEs) production for cancer therapy faces challenges. While various expression systems exist, Escherichia coli offers a preferred, large-scale option for rEs production, with bioengineering methods enhancing its clinical utility.
Area of Science:
- Biotechnology
- Molecular Biology
- Cancer Research
Background:
- Angiogenesis is crucial for tumor growth and metastasis, making its inhibition a key cancer therapy strategy.
- Endostatin (Es) is a promising anti-angiogenesis protein, but clinical use is limited by short half-life, serum instability, and high dosage requirements.
- Large-scale production of recombinant endostatin (rEs) is essential to overcome these limitations, yet its structural properties make production difficult and costly.
Purpose of the Study:
- To review and evaluate different expression systems for recombinant endostatin (rEs) production.
- To identify the most suitable system for large-scale rEs production considering cost and efficiency.
- To discuss bioengineering strategies for improving endostatin's stability and bioactivity.
Main Methods:
- Comparative analysis of mammalian, baculovirus, yeast, and Escherichia coli (E. coli) expression systems for rEs production.
- Evaluation of the advantages and disadvantages of each system in relation to endostatin's molecular properties.
- Review of molecular bioengineering techniques and sustained-release formulations.
Main Results:
- No single expression system was found to be universally superior for rEs production.
- The E. coli expression system presents a preferred option for large-scale rEs production due to a balance of advantages and disadvantages.
- Molecular bioengineering methods, including point mutation, moiety addition, fusion proteins, and nanoparticle formulations, show promise in enhancing endostatin's stability and bioactivity.
Conclusions:
- Escherichia coli is a suitable and preferred system for the large-scale production of recombinant endostatin.
- Bioengineering approaches are effective in overcoming the clinical limitations of endostatin, improving its stability and therapeutic potential.
More Related Videos
11:20Recombinant Protein Expression for Structural Biology in HEK 293F Suspension Cells: A Novel and Accessible Approach
Published on: October 16, 2014
11:42High Yield Expression of Recombinant Human Proteins with the Transient Transfection of HEK293 Cells in Suspension
Published on: December 28, 2015
